Relmada Therapeutics AI Stock Analysis
Want to see RLMD full AI Analyst Report?
Relmada Therapeutics (RLMD) AI Stock Analysis
Relmada Therapeutics
(NASDAQ:RLMD)
The score is constrained primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn), partially offset by a strong debt-free balance sheet and improved equity position. Earnings call content is a meaningful positive due to defined IND/Phase 3 timelines, favorable early clinical signals, and an operating runway projected through 2029. Technicals add modest support via improving short-term momentum, while valuation remains unattractive/less informative due to negative earnings and no dividend.
Relmada Therapeutics (RLMD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $449.08M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.36M
- Price to Earnings (P/E)
- -5.7
- Beta (1Y)
- 1.30
- Revenue Growth
- ―
- EPS Growth
- 58.31%
- Country
- US
- Employees
- 17
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Relmada Therapeutics Business Overview & Revenue Model
Company Description
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clin...
Relmada Therapeutics Earnings Call Summary
The call was broadly positive, driven by continued NDV-01 manufacturing progress, expected year-end 2026 IND filings, strong reported complete response rates, durable 18-month responses, a favorable safety profile, and cash resources expected to fund operations through 2029. The main negatives were two progressions to muscle-invasive disease, the limited evaluable 18-month cohort, ongoing manufacturing and stability work, the absence of a completed analysis for the second-line target population, and higher research and development spending and operating cash use.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Relmada expects to submit the IND for NDV-01 by year-end 2026, initiate the Phase 3 SPECTRUM program upon IND clearance, and file the sepranolone IND by year-end 2026, with the Phase 2 proof-of-concept study expected to begin upon IND clearance; if the IND gets cleared in a reasonable amount of time, that can be 30, 45 days, including the holidays in between, the company should be able to enroll the first patient within the first quarter of next year, and its current cash position is expected to fund company operations through 2029, including completion of the registrational Phase 3 NDV-01 SPECTRUM studies.
Relmada Therapeutics Financial Statement Overview
Summary
Pre-revenue profile with substantial ongoing losses (TTM net income about -$65.7M) and meaningful cash burn (TTM operating/free cash flow about -$51.9M) weigh heavily. Offsetting strengths include a debt-free balance sheet and a materially stronger equity base in TTM, improving financial flexibility despite negative returns.
Income Statement
12Very NegativeBalance Sheet
54NeutralCash Flow
23Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -64.93M | -57.39M | -79.98M | 4.91M | -157.04M | -125.75M |
| Net Income | -65.70M | -57.39M | -79.98M | -98.79M | -157.04M | -125.75M |
Balance Sheet | ||||||
| Total Assets | 205.30M | 94.00M | 45.82M | 97.55M | 152.91M | 223.33M |
| Cash, Cash Equivalents and Short-Term Investments | 202.12M | 93.01M | 44.91M | 96.32M | 148.32M | 211.91M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 11.56M | 7.49M | 10.30M | 12.19M | 12.47M | 15.06M |
| Stockholders Equity | 193.74M | 86.51M | 35.52M | 85.36M | 140.44M | 208.26M |
Cash Flow | ||||||
| Free Cash Flow | -51.86M | -45.79M | -51.76M | -51.66M | -103.80M | -91.87M |
| Operating Cash Flow | -51.86M | -45.79M | -51.76M | -51.66M | -103.80M | -91.87M |
| Investing Cash Flow | -187.62M | -48.14M | 51.56M | 50.45M | 19.73M | -54.12M |
| Financing Cash Flow | 243.81M | 93.56M | -40.34K | -98.46K | 45.02M | 187.94M |
Relmada Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RLMD, the sentiment is Positive. The current price of 4.21 is above the 20-day moving average (MA) of 3.71, above the 50-day MA of 3.77, and below the 200-day MA of 5.37, indicating a neutral trend. The MACD of 0.17 indicates Negative momentum. The RSI at 59.30 is Neutral, neither overbought nor oversold. The STOCH value of 64.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RLMD.
Relmada Therapeutics Risk Analysis
Relmada Therapeutics disclosed 82 risk factors in its most recent earnings report. Relmada Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksRelmada Therapeutics Peers Comparison
Overall Rating
RLMD58Neutral
HOWL50Neutral
SPRB47Neutral
PRLD38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 58Neutral | $449.19M | -5.69 | -37.25% | ― | ― | 58.31% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $47.64M | -1.71 | -187.29% | ― | ― | 64.23% | |
| 47Neutral | $124.47M | -1.24 | -118.22% | ― | -100.00% | 58.95% | |
| 38Underperform | $275.32M | -4.37 | -75.35% | ― | 220.34% | 55.73% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RLMD | Relmada Therapeutics Inc | 4.21 | 0.24 | 6.05% | |
| XBIT | XBiotech Inc. | 1.96 | -0.51 | -20.65% | |
| PRLD | Prelude Therapeutics, Inc. | 3.45 | 1.80 | 109.09% | |
| SPRB | Spruce Biosciences, Inc. | 43.31 | -65.53 | -60.21% | |
| HOWL | Werewolf Therapeutics, Inc. | 0.98 | 0.06 | 6.64% |
Relmada Therapeutics Corporate Events
Relmada Therapeutics Reports Third-Quarter Results and Business Update
PositiveOn November 12, 2026, Relmada Therapeutics reported third-quarter financial results and a business update. Initial 18-month results from its ongoing Phase 2 NDV-01 study showed that 86% of evaluable patients who reached 18 months remained in complete...
Relmada Therapeutics Announces Urology Chief Medical Officer Exit
NegativeRelmada Therapeutics, Inc. reported that the employment of Dr. Raj S. Pruthi as Chief Medical Officer – Urology ended on September 3, 2026. The departure marks a change in the company’s senior medical leadership in urology, which may influence its cl...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
